| We have entered a period of growth in the drug development industry, driven largely by financial investment and an increase in validated targets. This expansion has created a competitive need for finite drug development resources. As an employee of a preclinical testing company, I will be drawing on my experiences to comment on the value of the contract research organisation (CRO) and the growth of contract research, explaining these in the context of the biopharmaceutical industry. |
